Cardiovascular diseases (CVD) remain the number one cause of maternal mortality, with
over two-thirds of the cases being preventable. Social determinants of health (SDoH) …

Women have historically been underrepresented in clinical trials evaluating cardiovascular
devices. Existing initiatives through government agencies have made some progress, but …

Background Studies examining sex-related outcomes following percutaneous coronary
intervention (PCI) have reported conflicting results. Objectives The purpose of this study was …

Importance Despite bearing a disproportionate burden of heart failure (HF), Black and
Hispanic individuals have been poorly represented in HF clinical trials. Underrepresentation …

Objectives The aim of this study was to assess race-based differences in patients
undergoing percutaneous coronary intervention from a large pooled database of …

With the ever-increasing economic pressure to rapidly complete clinical trials, efforts to
include underrepresented patient populations such as African Americans, Hispanics, Native …

Cardiovascular disease (CVD) remains the leading cause of death in the United States.
However, percutaneous interventional cardiovascular therapies are often underutilized in …

In high-income countries, ischaemic heart disease is the leading cause of death in women
and men, accounting for more than 20% of deaths in both sexes. However, women are less …

Background Standardization of evidence‐based medical therapies has improved outcomes
for patients with non–ST‐segment–elevation myocardial infarction (NSTEMI). Although …

Background Data on racial disparities in major adverse cardiovascular events (MACE) and
major hemorrhage (HEM) after percutaneous coronary intervention are limited. Factors …